Current and emerging pharmacological therapy for non-alcoholic fatty liver disease

Table 2 Emerging medications for treatment of non- alcoholic fatty liver disease

Medication	Mechanism	Histology benefit
Obeticholic acid	Farnesoid X receptor agonist	Improvement of steatosis, lobular inflammation, ballooning and fibrosis
Aramchol	Inhibition of SCD1	Lacking data
Elafibranor	PPAR α/δ agonist	Improvement of steatosis and fibrosis
Cenicriviroc	Inhibition of CCR2/CCR5	Lacking data
Liraglutide	Glucagon-like peptide-1 agonist	Improvements in steatosis and hepatocyte ballooning

SCD1: Stearoyl CoA desaturase-1; PPAR: Peroxisome proliferator-activated receptor.